Literature DB >> 28412423

RV Contractile Function and its Coupling to Pulmonary Circulation in Heart Failure With Preserved Ejection Fraction: Stratification of Clinical Phenotypes and Outcomes.

Marco Guazzi1, Debra Dixon2, Valentina Labate3, Lauren Beussink-Nelson2, Francesco Bandera3, Michael J Cuttica4, Sanijv J Shah5.   

Abstract

OBJECTIVES: This study sought to investigate how right ventricular (RV) contractile function and its coupling with pulmonary circulation (PC) stratify clinical phenotypes and outcome in heart failure preserved ejection fraction (HFpEF) patients.
BACKGROUND: Pulmonary hypertension and RV dysfunction are key hemodynamic abnormalities in HFpEF.
METHODS: Three hundred eighty seven HFpEF patients (mean age 64 ± 12 years, 59% females, left ventricular ejection fraction 59 ± 7%) underwent RV and pulmonary hemodynamic evaluation by echocardiography (entire population) and right heart catheterization (219 patients). Patients were investigated by tricuspid annular plane systolic excursion (TAPSE) to pulmonary artery systolic pressure (PASP) relationship and stratified according to TAPSE/PASP ratio tertiles (1: <0.35; 2: 0.35 to 0.57; 3: >0.57). Specifically, TAPSE/PASP ratio was taken as a noninvasive index of RV to PC coupling based on the correlation with invasively evaluated RV systolic elastance/arterial elastance (r = 0.35; p < 0.0001).
RESULTS: Groups had similar prevalence of comorbidities except for a higher prevalence of atrial fibrillation and kidney dysfunction in tertile 1. Progressively increasing levels of natriuretic peptides, worse systemic and pulmonary hemodynamics, abnormal exercise aerobic capacity and ventilatory inefficiency were observed from the highest to lowest TAPSE/PASP tertile. TASPE/PASP correlated with pulmonary artery compliance (r = 0.69; p < 0.0001). Remarkably, the tertile 1 group distributed along the worse portion of the curve at lower pulmonary artery compliance and higher pulmonary vascular resistances. In addition, the TAPSE/PASP ratio emerged as an independent predictor of worse outcomes.
CONCLUSIONS: A thorough assessment of RV-PC coupling and RV contractile function stratify HFpEF phenotypes at different level of risk. These observations shift the interest toward therapeutic strategies that may benefit the right heart as primary unmet need in the complex pathophysiology of the HFpEF syndrome.
Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  heart failure with preserved ejection fraction; hemodynamics; pulmonary hypertension; right ventricle

Mesh:

Year:  2017        PMID: 28412423     DOI: 10.1016/j.jcmg.2016.12.024

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  73 in total

Review 1.  The Role of Echocardiography in Heart Failure with Preserved Ejection Fraction: What Do We Want from Imaging?

Authors:  Masaru Obokata; Yogesh N V Reddy; Barry A Borlaug
Journal:  Heart Fail Clin       Date:  2019-02-02       Impact factor: 3.179

2.  Right ventricle to pulmonary artery coupling in patients undergoing transcatheter aortic valve implantation.

Authors:  Ibrahim Sultan; Arturo Cardounel; Islam Abdelkarim; Arman Kilic; Andrew D Althouse; Michael S Sharbaugh; Aman Gupta; Jeff Xu; Miho Fukui; Marc A Simon; John T Schindler; Joon S Lee; Thomas G Gleason; João L Cavalcante
Journal:  Heart       Date:  2018-08-09       Impact factor: 5.994

Review 3.  Comprehensive Noninvasive Evaluation of Right Ventricle-Pulmonary Circulation Axis in Pediatric Patients with Pulmonary Hypertension.

Authors:  Pei-Ni Jone; Dunbar D Ivy
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-02-09

4.  Augmentation index predicts mortality in patients with aortic stenosis: an echo-tracking study.

Authors:  Olga Vriz; Paolo Palatini; Lucio Mos; Hani AlSergani; Igor Vendramin; Ugolino Livi; Francesco Antonini-Canterin; Julien Magne
Journal:  Int J Cardiovasc Imaging       Date:  2021-03-13       Impact factor: 2.357

5.  Age-changes in right ventricular function-pulmonary circulation coupling: from pediatric to adult stage in 1899 healthy subjects. The RIGHT Heart International NETwork (RIGHT-NET).

Authors:  Olga Vriz; Gruschen Veldman; Luna Gargani; Francesco Ferrara; Paolo Frumento; Michele D'Alto; Antonello D'Andrea; Sarah Aldosari Radaan; Rosangela Cocchia; Alberto Maria Marra; Brigida Ranieri; Andrea Salzano; Anna Agnese Stanziola; Damien Voilliot; Gergely Agoston; Filippo Cademartiri; Antonio Cittadini; Jaroslaw D Kasprzak; Ekkehard Grünig; Francesco Bandera; Marco Guazzi; Lawrence Rudski; Eduardo Bossone
Journal:  Int J Cardiovasc Imaging       Date:  2021-07-05       Impact factor: 2.357

Review 6.  Multimodality Imaging of the Right Ventricle.

Authors:  Christiane M Abouzeid; Tara Shah; Ansh Johri; Jonathan W Weinsaft; Jiwon Kim
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-09-25

7.  Right Ventricular Dysfunction and Its Contribution to Morbidity and Mortality in Left Ventricular Heart Failure.

Authors:  Amresh Raina; Talha Meeran
Journal:  Curr Heart Fail Rep       Date:  2018-04

8.  The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction.

Authors:  Yogesh N V Reddy; Masaru Obokata; Brandon Wiley; Katlyn E Koepp; Caitlin C Jorgenson; Alexander Egbe; Vojtech Melenovsky; Rickey E Carter; Barry A Borlaug
Journal:  Eur Heart J       Date:  2019-12-01       Impact factor: 29.983

Review 9.  Insights into the pulmonary vascular complications of heart failure with preserved ejection fraction.

Authors:  Yen-Chun Lai; Longfei Wang; Mark T Gladwin
Journal:  J Physiol       Date:  2018-12-30       Impact factor: 5.182

10.  Right atrial-right ventricular coupling in heart failure with preserved ejection fraction.

Authors:  Maximilian von Roeder; Johannes Tammo Kowallick; Karl-Philipp Rommel; Stephan Blazek; Christian Besler; Karl Fengler; Joachim Lotz; Gerd Hasenfuß; Christian Lücke; Matthias Gutberlet; Holger Thiele; Andreas Schuster; Philipp Lurz
Journal:  Clin Res Cardiol       Date:  2019-05-03       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.